| 产品编号 |
英文名称 |
CAS号 |
产品规格 |
价格 |
货期 |
| ZMR-07-1392 |
(4R,4'R)-2,2'-Cyclohexylidenebis[4-tert-butyl-4,5-dihydrooxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1384 |
(4R,4'R)-2,2'-Cyclopentylidenebis[4-tert-butyl-4,5-dihydrooxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1379 |
(4R,4'R)-2,2'-Cyclopentylidenebis[4,5-dihydro-4-(phenylmethyl)oxazole], 98%, (99% ee) |
[2005443-99-0] |
50mg |
咨询 |
3-5周 |
| ZMR-07-7210 |
(4R,4'R)-2,2'-Cyclopentylidenebis[4,5-dihydro-4-phenyloxazole], 95% (99% ee) |
[1246401-49-9] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1085 |
(4R,4'R,5S,5'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4,5-diphenyloxazole], 98% |
[1656253-81-4] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1378 |
(4R,4'R,5S,5'S)-2,2'-(1-Methylethylidene)bis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
[157904-67-1] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1398 |
(4R,4'R,5S,5'S)-2,2'-(Cycloheptane-1,1-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole), 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1390 |
(4R,4'R,5S,5'S)-2,2'-Cyclohexylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1382 |
(4R,4'R,5S,5'S)-2,2'-Cyclopentylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1076 |
(4R,4'R,5S,5'S)-2,2'-Cyclobutylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98% |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-07-1411 |
(4R,4'R,5S,5'S)-2,2'-Cyclopropylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
[229184-96-7] |
50mg |
咨询 |
3-5周 |
| ZMR-08-2004 |
(4R,5R)-(-)-2,2-Dimethyl-α;,α;,α;',α;'-tetra(1-naphthyl)-1,3-dioxolane-4,5-dimethanol, min. 97% (R,R)-1-Nph-TADDOL |
[137536-94-8] |
2g |
咨询 |
3-5周 |
| ZMR-22-0780 |
(4R,5R)-(-)-2,2-Dimethyl-α;,α;,α;',α;'-tetraphenyl-1,3-dioxolane-4,5-dimethanolato[1,2-bis(dimethoxy)ethane]titanium(IV) dichloride acetonitrile adduct |
[328123-04-2] |
1g |
咨询 |
3-5周 |
| ZMR-08-2008 |
(4R,5R)-(-)-2,2-Dimethyl-α;,α;,α;',α;'-tetraphenyl-1,3-dioxolane-4,5-dimethanol (R,R)-TADDOL |
[93379-48-7] |
2g |
咨询 |
3-5周 |
| ZMR-07-1376 |
(4R,5R)-N-(3,5-Bis(trifluoromethyl)phenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-amine, 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-0099 |
(4R,5S)-(+)-4-i-Propyl-5-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)-2-oxazolidinone, 99% |
[1432793-97-9] |
100mg |
咨询 |
3-5周 |
| ZMR-07-0096 |
(4R,5S)-(+)-4-Benzyl-5-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)-2-oxazolidinone, 99% |
[1391512-50-7] |
100mg |
咨询 |
3-5周 |
| ZMR-16-3006 |
(4R,5S)-3,3a,8,8a-Tetrahydroindeno[1,2-d]-1,2,3-oxathiazole-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1391532-95-8] |
1g |
咨询 |
3-5周 |
| ZMR-16-3021 |
(4R,5S)-4,5-Diphenyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1293372-65-2] |
1g |
咨询 |
3-5周 |
| ZMR-16-3008 |
(4S)-4-t-Butyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1206227-45-3] |
1g |
咨询 |
3-5周 |
| ZMR-16-3011 |
(4S)-4-i-Propyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1206227-46-4] |
1g |
咨询 |
3-5周 |
| ZMR-15-0563 |
(4S)-4-Hydroxy-2,6-bis(3,3'',5,5''-tetrakis(trifluoromethyl)-[1,1':3',1''-terphenyl]-5'-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine-4-oxide, 98%, (99% ee) |
N/A |
25mg |
咨询 |
3-5周 |
| ZMR-16-3031 |
(4S)-4-Phenyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[479687-23-5] |
1g |
咨询 |
3-5周 |
| ZMR-07-7105 |
(4S,4'S)-2,2'-[2-Phenyl-1-(phenylmethyl)ethylidene]bis[4-(1-methylethyl)-4,5-dihydrooxazole], 95%, (99% ee) |
[444575-98-8] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1219 |
(4S,4'S)-2,2'-(1-Phenylpropane-2,2-diyl)bis(4-phenyl-4,5-dihydrooxazole) (S)-BnPh-SaBOX |
[1404433-37-9] |
1g |
咨询 |
3-5周 |
| ZMR-07-1407 |
(4S,4'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-tert-butyloxazole], 98% |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1435 |
(4S,4'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-isopropyloxazole], 98%, (99% ee) |
N/A |
100mg |
咨询 |
3-5周 |
| ZMR-07-1235 |
(4S,4'S)-2,2'-(1,3-Bis[4-(t-butyl)phenyl)propane-2,2-diyl]bis(4-phenyl-4,5-dihydrooxazole) (S)-BTBBPh-SaBOX |
[1428328-51-1] |
1g |
咨询 |
3-5周 |
| ZMR-07-1073 |
(4S,4'S)-2,2'-(4,6-Dibenzofurandiyl)bis[4,5-dihydro-4-phenyloxazole], 98% |
[246040-77-7] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1401 |
(4S,4'S)-2,2'-(Cycloheptane-1,1-diyl)bis(4-tert-butyl-4,5-dihydrooxazole), 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1397 |
(4S,4'S)-2,2'-(Cycloheptane-1,1-diyl)bis(4-phenyl-4,5-dihydrooxazole), 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1389 |
(4S,4'S)-2,2'-Cyclohexylidenebis[4,5-dihydro-4-phenyloxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1393 |
(4S,4'S)-2,2'-Cyclohexylidenebis[4-tert-butyl-4,5-dihydrooxazole], 98%, (99% ee) |
[298693-04-6] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1079 |
(4S,4'S)-2,2'-Cyclobutylidenebis[4,5-dihydro-4-tert-butyloxazole], min. 95% |
[298693-02-4] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1062 |
(4S,4'S)-2,2'-Cyclopropylidenebis[4-tert-butyl-4,5-dihydrooxazole], 95% |
[195379-09-0] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1380 |
(4S,4'S)-2,2'-Cyclopentylidenebis[4,5-dihydro-4-(phenylmethyl)oxazole], 95%, (99% ee) |
[1003886-05-2] |
50mg |
咨询 |
3-5周 |
| ZMR-07-7218 |
(4S,4'S)-2,2'-Cyclopentylidenebis[4,5-dihydro-4-phenyloxazole], 98%, (99% ee) |
[1639791-77-7] |
100mg |
咨询 |
3-5周 |
| ZMR-07-1385 |
(4S,4'S)-2,2'-Cyclopentylidenebis[4-tert-butyl-4,5-dihydrooxazole], 95%, (99% ee) |
[298693-03-5] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1386 |
(4S,4'S)-2,2'-Cyclopentylidenebis[4-tert-butyl-4,5-dihydrooxazole], 95%, (99% ee) |
[298693-03-5] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1377 |
(4S,4'S,5R,5'R)-2,2'-(1-Methylethylidene)bis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
[157825-96-2] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1399 |
(4S,4'S,5R,5'R)-2,2'-(Cycloheptane-1,1-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole), 95%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1383 |
(4S,4'S,5R,5'R)-2,2'-Cyclopentylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-1412 |
(4S,4'S,5R,5'R)-2,2'-Cyclopropylidenebis[4,5-dihydro-4,5-diphenyloxazole], 95%, (99% ee) |
[229184-97-8] |
50mg |
咨询 |
3-5周 |
| ZMR-07-1391 |
(4S,4'S,5R,5'R)-2,2'-Cyclohexylidenebis[4,5-dihydro-4,5-diphenyloxazole], 98%, (99% ee) |
N/A |
50mg |
咨询 |
3-5周 |
| ZMR-07-0095 |
(4S,5R)-(-)-4-Benzyl-5-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)-2-oxazolidinone, 99% |
[857637-92-4] |
100mg |
咨询 |
3-5周 |
| ZMR-16-3005 |
(4S,5R)-3,3a,8,8a-Tetrahydroindeno[1,2-d]-1,2,3-oxathiazole-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1091606-66-4] |
1g |
咨询 |
3-5周 |
| ZMR-16-3020 |
(4S,5R)-4,5-Diphenyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1091606-63-1] |
1g |
咨询 |
3-5周 |
| ZMR-16-3003 |
(4S,5R)-4-Methyl-5-phenyl-1,2,3-oxathiazolidine-2,2-dioxide-3-carboxylic acid t-butyl ester, min. 97% |
[1091606-65-3] |
1g |
咨询 |
3-5周 |
| ZMR-15-2960 |
(4S,5S)-(+)-4,5-Bis(diphenylphosphinomethyl)-2,2-dimethyl-1,3-dioxolane, 99.5% (S,S)-DIOP |
[37002-48-5] |
1g |
咨询 |
3-5周 |
| ZMR-14-1810 |
(4S,5S)-2-Chloro-3,4-dimethyl-2,5-diphenyl-1-oxa-3-aza-2-silacyclopentane, min. 98% (~2:1 mixture of diastereomers) |
[680592-40-9] |
1g |
咨询 |
3-5周 |
